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Summary Objective Axitinib (AG-013736), an oral,
potent, and selective inhibitor of vascular endothelial
growth factor receptors 1, 2, and 3, is metabolized primarily
bycytochromeP450(CYP)3Awithminorcontributionsfrom
CYP1A2, CYP2C19, and glucuronidation. Co-administration
with CYP inhibitors may increase systemic exposure to
axitinib and alter its safety profile. This study evaluated
changes in axitinib plasma pharmacokinetic parameters and
assessed safety and tolerability in healthy subjects, following
axitinib co-administration with the potent CYP3A inhibitor
ketoconazole.Methods In this randomized, single-blind, two-
way crossover study, 32 healthy volunteers received placebo,
followed by a single 5-mg oral dose of axitinib, administered
either alone or on the fourth day of dosing with oral
ketoconazole (400 mg/day for 7 days). Results Axitinib
exposure was significantly increased in the presence of
ketoconazole, with a geometric mean ratio for area under the
plasma concentration–time curve from time zero to infinity
of 2.06 (90% confidence interval [CI]: 1.84–2.30) and a
geometric mean ratio for maximum plasma concentration
(Cmax)o f1 . 5 0( 9 0 %C I :1 . 3 3 –1.70). For axitinib alone or
with ketoconazole, Cmax occurred 1.5 and 2.0 h after
dosing, respectively. Adverse events were predominantly
mild; the most commonly reported treatment-related
adverse events were headache and nausea. Conclusions
Axitinib plasma exposures and peak concentrations were
increased following concurrent administration of axitinib
and ketoconazole in healthy volunteers. Axitinib alone
and in combination with ketoconazole was well tolerated.
These findings provide an upper exposure for expected
axitinib plasma concentrations in the presence of potent
metabolic inhibition.
Keywords Axitinib.Ketoconazole.Pharmacokinetics.
CYP3A.TaqMan® allelic discrimination.Simcyp®.
Corrected QT.Drug interaction
Introduction
Axitinib (AG-013736) is an oral, potent, and selective
inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3 that induces tumor regression [1]. Pre-clinical tumor
growth inhibition studies identified an effective axitinib
concentration of 0.28–0.85 nmol/L [1]. Axitinib plasma
concentrations observed in clinical trials after dosing (5 mg
twice daily [BID]) averaged 0.19±0.12 nmol/L [1]. Phase II
trials evaluating this dose in approximately 300 patients have
demonstrated antitumor activity combined with acceptable
tolerability across multiple tumor types, including metastatic
renal cell cancer, non-small cell lung cancer, melanoma, and
thyroid cancer [2–6]. The pharmacokinetics of axitinib are
generally linear [7]. Oral absorption occurs rapidly, with
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DOI 10.1007/s10637-010-9511-6peak plasma concentrations observed 1–4 h after dosing in
the fed state. Axitinib has an effective plasma terminal half-
life of 2–5 h and an oral absolute bioavailability of
approximately 58% [7, 8].
In vitro studies with recombinant cytochrome P450
(CYP) enzymes and human liver microsomes showed that
axitinib is primarily metabolized by oxidation via the
CYP3A isoenzyme and to a lesser extent by CYP1A2,
CYP2C19, and uridine diphosphate glucuronsyltransferase
(UGT) 1A1 [8]. The major circulating metabolites in
human plasma are an N-glucuronide product and a
sulfoxide; the putative metabolic pathways for axitinib
have been determined [9], and a schematic is provided in
Fig. 1. In a human liver microsomal preparation, ketoco-
nazole, a potent CYP3A inhibitor, blocked axitinib metab-
olism with a 50% inhibitory concentration (IC50)o f
0.4 μM. In vitro, ketoconazole has also been reported to
inhibit UGT2B7-mediated glucuronidation of zidovudine
and morphine and UGT1A1-mediated glucuronidation of
SN-38, the irinotecan metabolite [10]. These findings
suggest a mechanistic basis by which drugs that affect the
activity of CYP3A and UGT1A1 isozymes could alter the
pharmacokinetics of axitinib. This is further supported by
the observation of reduced axitinib exposure in a patient
who was also treated with phenytoin, a potent inducer of
multiple CYP enzymes, during the first-in-human (FIH)
phase I study of axitinib in patients with advanced solid
tumors [7]. Concurrent administration of phenytoin reduced
the area under the plasma concentration–time curve (AUC)
from time zero to 24 h (AUC0–24) and maximum plasma
concentration (Cmax) of axitinib approximately 10-fold.
Study protocols currently prohibit use of drugs known to
be potent inducers of the CYP3A and CYP1A2 isozymes
during axitinib treatment.
Co-administration of a CYP3A inhibitor such as keto-
conazole could have the opposite effect and lead to elevated
plasma exposure to axitinib, potentially increasing the
frequency and severity of adverse events. This randomized,
single-blind, two-way crossover study evaluated the effects
of repeated doses of ketoconazole plus a single axitinib
dose on axitinib pharmacokinetic parameters in healthy
volunteers. A separate study evaluated the effects of a
potent CYP3A inducer on axitinib plasma exposure in
healthy volunteers [8].
Methods
Subjects
Adults aged 18–55 years who were assessed as healthy
based on a detailed medical examination, which included
medical history, blood pressure (BP) and pulse-rate meas-
urements, a 12-lead electrocardiogram (ECG) test, and
clinical laboratory evaluations, were eligible to partici-
pate in the study. Subjects had a body mass index of 18–
30 kg/m
2, a total body weight >50 kg, and normal ECG
and resting BP measurement (<140/90 mm Hg). Volun-
teers agreed to abstain from strenuous physical activity
and consumption of products containing grapefruit, caf-
feine, xanthine, or alcohol from 2–4d a y sp r i o rt o
initiating the study until collection of the final pharmaco-
kinetic samples. Exclusion criteria were conditions that
might influence the absorption, distribution, metabolism,
orexcretion ofaxitiniborketoconazole: recenthistory ofdrug
abuse, high levels of alcohol consumption, or use of products
containing tobacco or nicotine; donation of >500 ml of
blood within 56 days before beginning study treatment;
use of prescription or non-prescription drugs or supple-
ments (other than acetaminophen) within 14 days before
initiating treatment (28 days for herbal supplements and
hormonal contraception methods or 6 months for depot
medroxyprogesterone acetate); or treatment with an
investigational agent or use of any known CYP450
enzyme-inducing or -inhibiting drug within 30 days of
beginning study medication.
Study design
This was a randomized, two-way crossover study conducted
in healthy volunteers. The primary objective was to charac-
terize changes in axitinib plasma pharmacokinetic parameters
when a single dose of axitinib was co-administered with
repeateddosesofketoconazoletohealthysubjects.Secondary
objectives included assessing the safety and tolerability of
axitinib administered with ketoconazole, as well as evaluating
the effects of a single axitinib dose on the corrected QT (QTc)
interval and BP when administered alone or in combination
with ketoconazole.
This study was approved by the institutional review
board or ethics committee of each participating center and
was carried out in accordance with the ethical principles
originating in or derived from the Declaration of Helsinki.
Additionally, this trial complied with informed consent
regulations and the International Conference on Harmoni-
zation Good Clinical Practice guidelines, as well as
applicable local laws and regulatory requirements. Written
informed consent was obtained prior to subjects entering
the study. Fig. 1 Schematic of axitinib metabolism in humans
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Placebo treatment was administered to all subjects on day –1
to characterize QT under the condition of no therapy. Using a
computer-generated randomization schedule, subjects were
assigned to receive either axitinib alone (treatment A) or
combination treatment with ketoconazole plus axitinib (treat-
ment B). Treatments were administered to subjects in one of
two different sequences (A→Bo rB →A) separated by a 14-
day wash-out period (Fig. 2). During treatment A, volunteers
received a single, oral, 5-mg dose of axitinib on day 1.
During treatment B, volunteers received oral doses of
k e t o c o n a z o l e4 0 0m g / d a yi nt h em o r n i n go nd a y s1 –7,
and a single 5-mg dose of axitinib administered with
ketoconazole on day 4.
Axitinib and placebo treatment were administered in a
single-blind manner, and ketoconazole treatment was not
blinded. Subjects received axitinib or placebo in the
morning after fasting overnight for at least 8 h; food and
beverages were permitted 4 h after dosing. The axitinib
tablet formulation used in this study was previously shown
to produce higher exposures in the overnight fasted state in
a phase I study conducted in patients with solid tumors [7]
and was the basis for administration of axitinib in the fasted
state in the current study. Ketoconazole was administered
with breakfast once daily in the morning, except on day 4
when it was administered simultaneously with axitinib after
an overnight fast of at least 8 h. During the first 4 h after
dosing, subjects were required to refrain from lying down,
except while BP, pulse rate, and ECG measurements were
obtained.
Assessments
Blood samples (5 ml) for determination of axitinib
pharmacokinetic profiles were collected on days 1–3a t
0 h (pre-dose) and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36,
and 48 h post-dose during treatment A. During treatment
B, samples were collected on days 4–8a t0h( p r e - d o s e )
and at 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and
96 h post-dose. Blood pressure and pulse rate were
recorded in triplicate at screening, and single measure-
ments were obtained on days –2a n d–1, days 1–3d u r i n g
treatment A, on the day before commencing the second
treatment, days 4–6d u r i n gt r e a t m e n tB ,a n da tt h ee n do f
the study. Standard 12-lead ECG tests were carried out at
screening, days –2a n d–1, day 1 during treatment A,
d a y s3a n d4d u r i n gt r e a t m e n tB ,a n da tt h ee n do ft h e
study. Assessments of ECG, BP, and pulse rate were
performed prior to the collection of blood samples at the
timepoints indicated above plus an additional assessment
10 h post-dose.
Safety and tolerability were assessed by monitoring
adverse events, vital signs, ECGs, and laboratory evalua-
tions, as well as through physical examinations. Adverse
events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events, version 3.0 (ctep.cancer.gov/protocoldevelopment/
electronic_applications/docs/ctcaev3.pdf).
Bioanalytical methods
Axitinib concentrations in potassium (K3) EDTA plasma
were measured using a validated liquid chromatography/
tandem mass spectrometric assay (Charles River Laborato-
ries, Worcester, MA) with a range of 0.1 to 25 ng/ml [7].
Due to axitinib light sensitivity, all sample processing and
bioanalytical procedures were performed under red light or
with appropriate protection from visible light. Plasma
samples were added to a 96-well opaque microtiter plate
and fortified with deuterium-labeled (d7) axitinib internal
standard, followed by addition of 1.0 M sodium bicarbon-
ate. The samples were extracted with ethyl acetate:hexanes
(75:25, v/v), centrifuged, and the supernatants were
evaporated to dryness under a gentle nitrogen stream in
microtiter plates heated to 35°C. Sample residues were
reconstituted in water/methanol/sodium bisulfite (75:25:0.5,
v/v/v) and eluted from a C18 column (XTerra® MS C18,
30×2.1 mm, 3.5 μm; Waters Corporation, Milford, MA)
using a multi-step gradient (mobile phase A = water, mobile
Randomization
Placebo 14-day
washout
14-day
washout
Treatment A
Day 1: axitinib 5 mg
Treatment A
Day 1: axitinib 5 mg
Treatment B
Days 1-7: ketoconazole
400 mg/day
Day 4: axitinib 5 mg 
Treatment B
Days 1-7: ketoconazole
400 mg/day
Day 4: axitinib 5 mg 
Placebo
Group B     A
Group A     B Fig. 2 Treatment overview
Invest New Drugs (2012) 30:273–281 275phase B = acetonitrile; 10–90% B in 3 min; 0.5 ml/min
flow rate) onto an API 3000® mass spectrometer (AB
Sciex, Ontario, Canada) with an electrospray ionization
source. Detection was in positive ion mode with multiple
reaction monitoring (mass transition [m/z] 387→355 and
394→360 for axitinib and axitinib-d7). Duplicate quality
control (QC) samples at three concentration levels spanning
the assay range (low, medium, and high) were included in
each analytical run to measure assay performance. Inter-
assay precision and accuracy were determined by QC
samples from across all study sample runs. Precision was
within 12% coefficient of variation (CV), while overall bias
(expressed as percent relative error) was within 5.5%. No
plasma metabolites were characterized in the study.
Genotyping of drug-metabolizing enzymes was carried
out using polymerase chain reaction (PCR) to amplify DNA
samples for all assays performed in this study (Pfizer-Ann
Arbor, Worldwide Safety Sciences, Ann Arbor, MI). In
particular, the following variants of UGT1A1 were
assessed: UGT1A1*60, UGT1A1-3156 (-3156 G→A
nucleotide change), UGT1A1 Promoter TA repeat (*28,
*36, *37), UGT1A1*6 and UGT1A1*27. Genotyping for
the CYP2C19 *2, *3, and *17 alleles was also conducted.
The TaqMan® Allelic Discrimination procedure was used
for detection of all alleles, with the exception of the
CYP3A4*2 (MassEXTEND™; Sequenom, San Diego,
CA) and UGT1A1*28 (sequencing) genotyping assays.
TaqMan® allelic discrimination assay
TaqMan® allelic discrimination employs the 5′-nuclease
activity of AmpliTaq Gold® DNA polymerase to allow
direct detection of PCR products by the release of a
fluorescent reporter. Two TaqMan® probes (Applied Bio-
systems, Carlsbad, CA) were used in this assay, one probe
for each allele. Each probe consists of an oligonucleotide
with a 5′ reporter (TET™ [tetrachloro-6-carboxyfluores-
cein]/VIC® or FAM® [6-carboxyfluoroscein] dye and a 3′-
quencher dye [TAMRA™ (6-carboxytetramethylrhod-
amine)] or a non-fluorescent quencher). An intact probe
results in quenching of the reporter dye fluorescence.
During the annealing phase of PCR, forward and reverse
primers hybridize to the flanking region of the polymorphic
site. In addition, the TaqMan® probes hybridize to the target
polymorphic site within the PCR product. The reporter dye is
cleaved by the Taq Gold® enzyme, resulting in an increase in
the reporter dye fluorescence. By measuring the intensities of
TET™/VIC® (allele1 or homozygouswildtype) and FAM™
(allele 2 or homozygous variant) signal, the specific genotype
of an allele is discriminated.
Individual reaction plates with 20 ng of genomic DNA per
reaction were used. Master mixes were prepared for each assay
performed, and controls for both no template and each allele
were included for each plate. After master mix (10X PCR
buffer with MgCl2, forward and reverse primers, TaqMan®
probes, deoxynucleotides, and AmpliTaq Gold® DNA poly-
merase) had been added to the controls and unknown DNA
samples, plates were sealed and PCR cycling (GeneAmp®
PCR System 9700, Applied Biosystems) performed. The
sealed 96-well plates were then transferred to the ABI 7700®
(Applied Biosystems) and fluorescence data collected.
Simcyp® simulations
A Simcyp®-based simulation (Simcyp® Population-based
ADME Simulator, version 6.0 [Simcyp Ltd, Sheffield, UK]
on Microsoft Windows® XP [Redmond, WA]) was per-
formed to assess changes in axitinib plasma concentrations
with co-administration of ketoconazole (inhibitor) in
healthy volunteers. Simcyp® uses the relationship between
the inhibitor concentration at the active site in vivo and the
inhibition constant (Ki) determined in vitro to predict the
effects of drug–drug interactions involving CYP enzymes.
Competitive inhibition, induction, and/or mechanism-based
inhibition can be investigated using this software [11].
A Simcyp® modelwasdevelopedfor axitinibusingin vitro
and clinical pharmacokinetic parameters for axitinib (input
parameters are shown in Table 1). The required Simcyp®
model for ketoconazole was available within Simcyp® as an
inhibitor file. Due to the inability to determine glucuronida-
tion clearance from in vitro tissues accurately, the following
approach was used. Systemic clearance (CLsys) for axitinib
was determined from a previous study in healthy volunteers
who received intravenous axitinib (1 mg). In vivo CLsys was
then converted to intrinsic clearance (CLint)u s i n ga m o u n to f
microsomal protein per gram of liver and liver weight to yield
aC L int of 500 μl/min/mg microsomal protein. Contribution
of CYP3A and glucuronidation to total CLint was determined
through sensitivity analyses to be 50% (CYP3A4=250 μl/
min/mg microsomal protein) and 30% (non–CYP-mediated
clearance=150 μl/min/mg), respectively, when simulations
with ketoconazole were conducted. The remaining 20% of
clearance was attributed to non-metabolic pathways (4.2 L/h).
Physiologic variability (healthy Northern European
Caucasians: height, weight, age, etc.) and variation in
phenotype were calculated using parameters within the
Simcyp® software. Dose, dose interval, and duration of
administration of axitinib and ketoconazole were set
according to the clinical protocol. Simcyp® predicts the
mean value as well as the distribution in the population
for the effect by applying a Monte Carlo approach.
Population simulations were performed using 100 North-
ern European Caucasians aged 20–50 years (1:1 male/
female) in 10 trials, with each trial containing 10
subjects. To prevent bias, the Simcyp® end-user did not
have access to the clinical drug–drug interaction results.
276 Invest New Drugs (2012) 30:273–281Statistical and pharmacokinetic analyses
Based on an IC50 of 0.4 μM for ketoconazole-mediated
inhibition of axitinib metabolism observed in human liver
microsomal preparations, ketoconazole 400 mg was pre-
dicted to result in a 1.8-fold increase in axitinib geometric
mean AUC from time zero to infinity (AUC0–∞) and a 1.5-
fold increase in geometric mean Cmax.
The standard deviation (SD) of the difference between
(natural log) AUC0–∞ of axitinib plus ketoconazole and
axitinib alone was estimated to be 0.42, based on variability
in axitinib pharmacokinetics observed in the FIH phase I
study in patients with solid tumors [7]. The sample size was
calculated as 24 subjects (12 per sequence) to provide 80%
power to ensure that the lower limit of the 90% confidence
interval (CI) for the AUC ratio was above 1.6 (a 60%
increase), if ketoconazole treatment increased axitinib
exposure by 100%.
Data analyses included all subjects who received at least
one dose of study medication (placebo, axitinib, or
ketoconazole). In addition, evaluable pharmacokinetic data
were required for analyses of pharmacokinetic parameters,
and at least one baseline and post-baseline BP measurement
were needed for BP analyses.
Pharmacokinetic evaluation of axitinib was performed
with WinNonlin®, version 4.01 (Pharsight, Mountain View,
CA) using a non-compartmental approach. Estimated
axitinib pharmacokinetic parameters included AUC, Cmax,
and half-life (t1/2). The primary analysis for the study was
based on axitinib AUC0–∞. This value was log-transformed
and analyzed using a mixed-effects model with treatment,
period, and sequence as fixed effects and subject (nested
within sequence) as the random effect. The 90% CI for the
difference in the means of the log-transformed AUC0–∞ was
calculated. The antilogs of the confidence limits obtained
constituted the 90% CI for the ratio of the geometric mean
of ketoconazole plus axitinib compared with axitinib alone.
Secondary analyses were performed using axitinib AUC
from time zero to the time of last quantifiable concentration
(AUClast) and Cmax in a similar fashion.
Results
Subject characteristics and disposition
A total of 35 subjects were enrolled, 20 of whom were
randomized to group A→B and 15 of whom were
randomized to group B→A. Baseline characteristics
were comparable between subjects in the two groups
(Table 2). The majority of participants were male (91.4%)
and the median age was 32 years (range: 19–54 years).
Thirty-two subjects received at least one dose of axitinib;
28 subjects (80% of the 35 enrolled subjects) completed
the study. The remaining seven subjects discontinued at
the investigator’s discretion, i.e., serum chemistry abnor-
malities before receiving axitinib (n=2); positive cotinine
test after the washout period (n=1); difficulty swallowing
(n=1), withdrawal of consent (n=2), or terminated due to
an adverse event assessed as unrelated to treatment (n=1,
grade 1 increased serum creatinine).
Pharmacokinetics
In all, 32 subjects were included in the pharmacokinetic
analysis, which included data for 31 subjects treated with
axitinib alone and 28 subjects treated with axitinib plus
ketoconazole.
Table 1 In vitro input parameters used in Simcyp® model
Input parameter Value Data source
Molecular weight 386.47
Log P 3.1 In vitro determination
B/P ratio 0.79 In vitro determination
fu plasma 0.02 In vitro plasma protein binding
fa 1 Assumption
ka (1/h) 0.7 Estimated as ~ 1/Tmax;T max from clinical data
Vss (L/kg) 1 Clinical data
fu microsomal 1 Simcyp® in silico calculator
Q gut (L/h) 10 Based upon Caco-2 cell permeability data
CLint (ul/min/mg – microsomal protein) 250 Experimental; for P450 contribution
Additional undefined HLM CLint 150 Experimental; for non-P450 (glucuronidation) contribution
P partition coefficient, B/P ratio blood to plasma ratio for axitinib, fu plasma fraction of drug unbound in plasma, fa fraction absorbed from
gastrointestinal tract, ka first-order rate of absorption, Vss volume of distribution at steady state, fu microsomal fraction of drug unbound in
microsomal fraction, Qgut intestinal blood flow, CLint intrinsic clearance, HLM human liver microsomes
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lower limit of quantification (0.100 ng/ml), demonstrating
that the washout period between treatments A and B was
sufficient. QC assay performance had an average accuracy
within 6% and average precision was within 13% CV. As
expected, median plasma concentrations of axitinib were
higher following combination treatment with ketoconazole
and axitinib compared with axitinib treatment alone
(Fig. 3). Similarly, axitinib exposure was significantly
increased in the presence of ketoconazole, with a geometric
mean ratio for AUC0–∞ of 2.06 (90% CI: 1.84–2.30) and a
geometric mean ratio for Cmax of 1.50 (90% CI: 1.33–1.70)
(Table 3). The mean plasma t1/2 of axitinib increased
following co-administration with ketoconazole to 13.1 h
(SD: 8.85), compared with 9.44 h (SD: 9.98) following
axitinib treatment alone. Ketoconazole treatment did not
appear to have any effect on axitinib median time to reach
Cmax (Tmax). Values for Tmax were 1.50 h (range: 1.00–
3.00) for axitinib alone and 2.00 h (range: 1.00–4.13) for
axitinib plus ketoconazole.
Genotypic analysis of axitinib drug-metabolizing enzymes
Since axitinib metabolism has minor contributions from
two genetically polymorphic enzymes, CYP2C19 and
UGT1A1, genotyping for these enzymes was included here
and in most axitinib studies conducted in healthy volun-
teers. The intent of the genotyping is to conduct a pooled
meta-analysis of the influence of polymorphic enzymes on
inter-subject variability in axitinib drug exposure. Due to a
Table 2 Subject characteristics at baseline
Group A→B( n=20) Group B→A( n=15) Total (N=35)
Sex, n (%)
Male 18 (90.0) 14 (93.3) 32 (91.4)
Female 2 (10.0) 1 (6.7) 3 (8.6)
Age, median (min, max), years 33.5 (19, 54) 32.0 (21, 53) 32.0 (19, 54)
Race, n (%)
Black 2 (10.0) 2 (13.3) 4 (11.4)
Caucasian 10 (50.0) 9 (60.0) 19 (54.3)
Hispanic/Latino 7 (35.0) 3 (20.0) 10 (28.6)
Other 1 (5.0) 1 (6.7) 2 (5.7)
Systolic BP at baseline, median (min, max), mm Hg 114.0 (96, 135) 112.0 (98,135) 114.0 (96, 135)
Diastolic BP at baseline, median (min, max), mm Hg 67.5 (58, 86) 72.0 (62, 83) 70.0 (58, 86)
BP blood pressure
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Fig. 3 Median axitinib
concentration-time profiles
following treatment with
axitinib alone (n=31) or axitinib
plus ketoconazole (n=29), linear
scale a and log scale b
278 Invest New Drugs (2012) 30:273–281lack of statistical power, it was not possible to assess the
effect of genotype on axitinib pharmacokinetics from this
study alone.
Simcyp® simulation
The Simcyp® simulation was conducted using a design that
mirrored the clinical ketoconazole drug interaction study
design. The Simcyp® simulations predicted a 2.08-fold
increase in AUC and a 1.41-fold increase in Cmax for
axitinib in the presence of ketoconazole. The overall
predicted shift in axitinib plasma concentration by Simcyp®
was similar to that observed clinically in the presence of
ketoconazole (2.06-fold increase in AUC0–∞; 1.50-fold
increase in Cmax).
Pharmacodynamics
Meantime-matchedchangesfrom baselineinBPwereminimal
and followed similar trends for axitinib treatment alone and in
combination with ketoconazole (Fig. 4). Mean values for
systolic and diastolic BP were within normal ranges. Findings
from the QTc analysis will be reported elsewhere.
Safety and tolerability
Adverse events were generally mild and resolved without
treatment, as expected in this population of healthy
volunteers. One subject (2.9% of all subjects) in group
A→B experienced grade 2 nausea and vomiting during
treatment with axitinib plus ketoconazole. No action was
required, and the adverse event resolved before the end of
the study. All other treatment-emergent adverse events,
regardless of causality, were grade 1. No grade 3 or 4
laboratory abnormalities were reported. Treatment-related
adverse events were reported in eight volunteers (40.0%) in
group A→B and in one volunteer (6.7%) in group B→A.
Treatment-related adverse events primarily affected the
nervous system (e.g., dizziness or headache) or gastroin-
testinal system (e.g., nausea) (Table 4). Most treatment-
related adverse events occurred during treatment with
ketoconazole alone or with axitinib plus ketoconazole.
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Table 3 Summary of axitinib PK parameters (evaluable population; n=32)
Geometric LS mean (95% CI) Statistical comparison
Axitinib (n=31) Axitinib + ketoconazole (n=28) Geometric LS mean ratio 90% CI
AUC0–∞ (ng·h/ml) 196.7 (162.0–238.8) 404.8 (332.3–493.2) 2.06 1.84–2.30
AUClast (ng·h/ml) 193.8 (159.9–234.9) 401.9 (330.1–489.3) 2.07 1.86–2.31
Cmax (ng/ml) 51.0 (43.9–59.3) 76.7 (65.6–89.7) 1.50 1.33–1.70
AUC0–∞ area under the plasma concentration–time curve from time zero to infinity, AUClast area under the plasma concentration–time curve from
time zero to the time of last quantifiable concentration, CI confidence interval, Cmax, maximum plasma concentration, LS, least squares
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Data from this study represent maximized axitinib expo-
sures obtained when axitinib is co-administered with
ketoconazole, a drug that inhibits CYP3A activity. Con-
comitant treatment with ketoconazole significantly in-
creased axitinib exposure, resulting in a ~2-fold increase
in geometric mean axitinib AUC0–∞ and a ~1.5-fold
increase in geometric mean Cmax. These findings support
the exclusion criteria in ongoing axitinib studies for patients
to avoid concurrent treatment with potent inhibitors of
CYP3A. These data are also useful in quantitatively
predicting the magnitude of change in axitinib exposure
(i.e., no more than 2-fold) expected when potent CYP3A
inhibitors other than ketoconazole are administered together
with axitinib.
Based on data from human liver microsomal prepara-
tions (unpublished data), ketoconazole was predicted to
result in a 1.8-fold increase in axitinib geometric mean
AUC0–∞. Similarly, the Simcyp® prediction was a 2.08-fold
increase in axitinib plasma concentrations in the presence of
ketoconazole. The clinical result (2.06-fold increase) was
similar to these pre-clinical predictions and confirms the
validity of this simulation.
Although this study was not sufficiently powered to
evaluate the effect of genotypic variation in drug-
metabolizing enzymes on axitinib pharmacokinetics, data
from this trial were included in a separate population
pharmacokinetic analysis that evaluated the potential effect
of the UGTA1A1*28 genotype on axitinib pharmacokinetics
in 119 healthy volunteers [12]. In the population pharma-
cokinetics model, the UGT1A1*28 genotype was not
identified as a significant covariate for oral clearance (CL/
F). However, the model predicted that subjects who are
homozygous or heterozygous for this mutation are predis-
posed to have reductions in CL/F of 10% and 5%,
respectively, compared with individuals homozygous for
the wild-type gene. At the highest simulated dose (10 mg
BID), the upper 90% bound for the predicted AUC
distribution in homozygous variant subjects was lower than
the plasma exposure associated with unacceptable toxicity
in the FIH phase I dose-escalation study in patients [7].
Based on these findings, axitinib dose modification in
patients based on UGT1A1*28 genotype is not warranted at
this time.
Administration of a single dose of axitinib in combination
withrepeatedketoconazoletreatmentwaswelltolerated.Most
treatment-related adverse events affected the nervous or
gastrointestinal systems, with headache and nausea reported
most frequently during combination treatment (n=10.7%
each). With the exception of one patient who experienced
grade 2 nausea and vomiting, all other treatment-related
adverse events were mild in severity (grade 1). No clinically
significant effects on diastolic or systolic BP were observed
for axitinib plus ketoconazole treatment compared with
axitinib treatment alone. Treatment-related adverse events
reported for axitinib treatment alone were similar to those
reported in other clinical trials with axitinib [2–6].
In conclusion, axitinib treatment was well tolerated in
this study, both alone and in combination with ketoco-
nazole. However, as predicted, axitinib and ketoconazole
co-administration significantly increased axitinib plasma
exposure and peak concentrations in healthy volunteers
compared with axitinib alone. Concomitant treatment
with potent CYP3A4 inhibitors and axitinib should be
avoided since the combination may increase the frequen-
cy or severity of adverse events.
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AE, n (%) Axitinib (n=32) Ketoconazole (n=29) Axitinib+ketoconazole (n=28)
Grade 1
b Grade 1
b Grade 1 Grade 2
Any AE 2 (6.3) 3 (10.3) 5 (17.9) 1 (3.6)
Headache NOS 1 (3.1) 3 (10.3) 3 (10.7) 0
Nausea 0 2 (6.9) 2 (7.1) 1 (3.6)
Dizziness 0 2 (6.9) 1 (3.6) 0
Loose stools 1 (3.1) 0 1 (3.6) 0
Dysgeusia 1 (3.1) 0 0 0
Blurred vision 0 1 (3.4) 0 0
Gastritis NOS 0 1 (3.4) 0 0
Vomiting NOS 0 0 0 1 (3.6)
Table 4 Treatment-related
adverse events (AEs) for
prescribed treatment at time
of AE
a
NOS not otherwise specified
a No treatment-related AEs were
reported during prescribed
treatment with placebo
bNo AEs grade ≥2 were reported
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